Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study

To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019. This is a retrospective cohort study. Rr-TB patients we...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases Vol. 124; pp. 81 - 88
Main Authors: Jouego, Christelle Géneviève, Gils, Tinne, Piubello, Alberto, Mbassa, Vincent, Kuate, Albert, Ngono, Annie, Belinga, Edwige, Etoundi, Antoine, Tollo, Alphonse, Makondi, Danielle, André, Emmanuel, Masumbe, Palmer, Lynen, Lutgarde, Noeske, Jürgen, Decroo, Tom
Format: Journal Article
Language:English
Published: Elsevier Ltd 01.11.2022
Elsevier
Subjects:
Cameroon
Fluoroquinolone and second-line injectable resistance
Rr-TB
Standard regimen
Fluoroquinolone and second-line injectable resistance
Cameroon
Rr-TB
Standard regimen
ISSN:1201-9712, 1878-3511, 1878-3511
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019. This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively. Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex. Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2022.09.012